AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has successfully completed the acquisition of Cerevel Therapeutics Holdings, Inc. on August 1, 2024, as per the Merger Agreement dated December 6, 2023. Following the merger, AbbVie has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission to register shares of common stock that may be issued under the Cerevel 2020 Equity Incentive Plan. This plan has been assumed by AbbVie, and certain restricted stock unit awards previously granted under the plan have been converted into awards for AbbVie common stock. These converted awards will continue to be governed by the terms of the Cerevel Plan post-merger. The registration of these shares enables the settlement of the converted awards for AbbVie employees who held equity in Cerevel.

AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has successfully completed the acquisition of Cerevel Therapeutics Holdings, Inc. on August 1, 2024, as per the Merger Agreement dated December 6, 2023. Following the merger, AbbVie has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission to register shares of common stock that may be issued under the Cerevel 2020 Equity Incentive Plan. This plan has been assumed by AbbVie, and certain restricted stock unit awards previously granted under the plan have been converted into awards for AbbVie common stock. These converted awards will continue to be governed by the terms of the Cerevel Plan post-merger. The registration of these shares enables the settlement of the converted awards for AbbVie employees who held equity in Cerevel.